Evoke Pharma, Inc. (EVOK) Financial Statements (2023 and Earlier)

Company Profile

Business Address 420 STEVENS AVENUE
SOLANA BEACH, CA 92075
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments9,1458,0695,6645,3197,6799,0078,691
Cash and cash equivalents9,1458,0695,6645,3197,6799,0078,691
Receivables29523     
Inventory, net of allowances, customer advances and progress billings186236     
Inventory186236     
Prepaid expense924922582329251268833
Other current assets1230   8 
Total current assets:10,5619,2816,2465,6487,9309,2839,524
Noncurrent Assets
Operating lease, right-of-use asset12142139
Other noncurrent assets 12121212128
Total noncurrent assets:121531501212128
TOTAL ASSETS:10,5739,4346,3965,6607,9429,2949,532
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:8741,2741,0334761,049478928
Employee-related liabilities5191,0168431,1581,026933761
Other undisclosed accounts payable and accrued liabilities355257190(682)23(455)167
Debt  139   146
Other undisclosed current liabilities5326,2628431,1581,026933761
Total current liabilities:1,4067,5362,0151,6342,0751,4121,834
Noncurrent Liabilities
Long-term debt and lease obligation5,0005,000    4,233
Long-term debt, excluding current maturities5,0005,000    4,233
Liabilities, other than long-term debt612113     
Accounts payable and accrued liabilities612113     
Other undisclosed noncurrent liabilities    3,7014,095 
Total noncurrent liabilities:5,6125,113  3,7014,0954,233
Total liabilities:7,01812,6492,0151,6345,7765,5076,067
Stockholders' equity
Stockholders' equity attributable to parent3,555(3,215)4,3814,0252,1663,7883,465
Common stock3322211
Additional paid in capital110,97595,66890,10882,62873,20362,59651,525
Accumulated deficit(107,423)(98,885)(85,730)(78,605)(71,039)(58,809)(48,061)
Total stockholders' equity:3,555(3,215)4,3814,0252,1663,7883,465
TOTAL LIABILITIES AND EQUITY:10,5739,4346,3965,6607,9429,2949,532

Income Statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues1,61823     
Cost of revenue
(Cost of Goods and Services Sold)
(30)      
Gross profit:1,58823     
Operating expenses(9,770)(13,070)(7,154)(8,015)(11,231)(10,544)(11,818)
Other undisclosed operating income30      
Operating loss:(8,152)(13,047)(7,154)(8,015)(11,231)(10,544)(11,818)
Nonoperating income (expense)(386)(107)29449(999)(204)(303)
Interest and debt expense(500)(113)    (511)
Net loss:(9,038)(13,268)(7,126)(7,566)(12,230)(10,749)(12,632)
Other undisclosed net income attributable to parent500113    511
Net loss available to common stockholders, diluted:(8,538)(13,155)(7,126)(7,566)(12,230)(10,749)(12,121)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(9,038)(13,268)(7,126)(7,566)(12,230)(10,749)(12,632)
Comprehensive loss, net of tax, attributable to parent:(9,038)(13,268)(7,126)(7,566)(12,230)(10,749)(12,632)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: